<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Unlocking the Cell Surface to Transform Oncology Drug Discovery

Link surface expression to treatment response and accelerate the path from target discovery to clinical validation.

Built on Human Tumors That Reflect the Clinic 

The tumor surface is one of the most important landscapes in oncology. It’s where therapies engage, where resistance takes hold, and where many of the next-generation targets will be found. Yet most existing datasets leave this critical biology hidden. They’re noisy, fragmented, and built on cell lines that fail to capture the complexity of real human disease.

Champions Oncology has changed that. By profiling human tumors directly, using a proprietary protocol that isolates the plasma membrane with extraordinary precision, we’ve built the most clinically relevant cell surface proteomics dataset available today. For the first time, researchers can see the surfaceome in sharp focus and connect those insights to meaningful biology.

Every dataset begins with our living tumor bank, derived from advanced-stage, metastatic tumors collected from patients who have relapsed after standard therapies. These tumors are preserved in their native state, maintaining the heterogeneity and clinical relevance that conventional systems lose. Integrated with genomics, transcriptomics, proteomics, and pharmacology, they provide a foundation that mirrors the biology of human disease and delivers insights you can trust.

Solving the Surfaceome Problem 

Traditional cell surface profiling has always been compromised. Intracellular contamination clouds the signal. Cell-line models misrepresent how proteins are expressed in real tumors. Public datasets are small, inconsistent, and difficult to compare. The result is a blurred, unreliable picture of the tumor surface.

Our solution eliminates that noise. Human tumors are kept in a biologically intact environment, then processed using a proprietary workflow that gently separates plasma membranes from the rest of the cell. By quantifying surface, intracellular, and whole-cell fractions in parallel, we can measure true enrichment and reveal what is actually present at the tumor surface. The result is a dataset that is clean, interpretable, and reproducible, a breakthrough resource for translational oncology. 

iStock-1206633493

 

Access the Champions Data Room 

For partners ready to explore the depth of our data, Champions provides secure access to our Data Room. Here you can evaluate sample datasets, review enrichment metrics, and see how our cell surface proteomics integrate with broader multiomic profiles. 

  • Discover how surface expression correlates with treatment response. 
  • Explore new target opportunities validated in real human tumors.
  • Assess the quality and interpretability of our data for your own programs.
iStock-2220084686

From Data to Discovery 

With this enriched view of the tumor surface, new opportunities open up. Researchers can discover and validate novel ADC and radiopharmaceutical targets with greater confidence. Biomarker hypotheses become more accurate by measuring proteins directly rather than inferring from RNA. Patient stratification strategies gain power by linking surface expression with clinical response.

Our surfaceome data is already helping biopharma identify targets, select the right tumor models, and uncover expression trends that traditional approaches consistently miss. It’s a powerful advantage for programs racing to deliver new therapies to patients. 

Redefining the Future of Target Discovery

Cell surface proteomics is more than another dataset. It is the next frontier in oncology research. Champions Oncology’s platform integrates surface biology into the deepest multiomic dataset in the industry, creating a resource with unmatched clinical and translational value. By making the invisible visible, we are equipping drug developers with the insights needed to design therapies that are more precise, more effective, and more impactful for patients. 

iStock-2148124383
pharma_stock

De-risk Trials and Unlock New Strategies

Developing therapies for late-stage patients requires data that reflects the complexity of human disease. Champions’ surfaceome dataset reveals how targets are expressed in advanced, metastatic tumors, helping pharma teams validate mechanisms, understand resistance, and stratify patients with precision. This reduces trial risk and opens opportunities for more effective combination strategies. 

Turn better data into better decisions.

Contact us today.

Access the Data Room

See the Data for Yourself  


Champions Oncology provides secure access to our Data Room, giving partners the opportunity to explore the depth and power of our cell surface proteomics dataset. This is where discovery becomes real — where you can review sample outputs, explore enrichment metrics, and see how surface biology connects with clinical response.

  • Evaluate the world’s most clinically relevant surfaceome dataset. 
  • Explore correlations between surface expression and treatment outcomes. 
  • Identify novel ADC and radiopharma targets validated in human tumors. 

Ready to unlock the surfaceome?

 

Let’s Build the Future of Cancer Research Together

Take this opportunity to align your platform, pipeline, or portfolio with the dataset built for modern drug discovery.

Frequently Asked Questions
What is the "surfaceome," and why does it matter in oncology drug discovery?

The surfaceome refers to the complete set of proteins expressed on the cell surface. In oncology, these proteins are critically important because they mediate how cancer cells interact with their environment — including immune surveillance, drug response, and metastasis. They are also the primary targets for antibody-drug conjugates (ADCs), CAR-T therapies, and radiopharmaceuticals. Understanding the true surfaceome enables more accurate target selection and more precise patient stratification.

How is Champions Oncology’s dataset different from other surface proteomics data?

Most publicly available datasets are derived from cell lines, which often fail to reflect the complexity and heterogeneity of real tumors. Champions’ dataset is built directly from human tumors, using a proprietary plasma membrane isolation protocol that eliminates intracellular contamination and enhances specificity. This approach yields clean, reproducible, and clinically relevant data that truly represents the tumor surface in advanced disease.

What types of tumors are included in the dataset?

Our dataset originates from our living tumor bank, composed of advanced-stage, metastatic tumors collected from patients who have relapsed after standard treatments. These tumors preserve their native state and maintain the cellular heterogeneity critical for translational research.

What makes your surfaceome profiling method more accurate?

Champions uses a biochemically validated method that fractionates tumor samples into surface, intracellular, and whole-cell proteomes. By quantifying each fraction in parallel, we can measure true protein enrichment at the cell surface — filtering out noise from lysed organelles or background contamination. This results in a high-fidelity view of surface protein expression.

How does this dataset integrate with other omics data?

Surface proteomics is integrated with Champions’ multiomic platform, including genomics, transcriptomics, and pharmacology. This allows researchers to correlate surface protein expression with genetic drivers, treatment response, and drug sensitivity — offering a more comprehensive view of tumor biology and actionable insights for drug development.

Can I access the raw or sample data before committing to a partnership?

Yes. Qualified partners can request access to our secure Data Room, where they can explore sample datasets, protein enrichment metrics, and multiomic integration. This enables data teams to evaluate interpretability and relevance for their internal programs before engagement.

What are common use cases for this dataset in drug development?

Champions’ cell surface proteomics dataset is used across the drug development pipeline to improve decision making and reduce risk. ADC and radiopharma teams use it to confirm that their chosen targets are truly expressed on human tumors before investing in costly preclinical or clinical programs. Pharma and biotech groups apply it to build more accurate biomarker hypotheses, stratify patients based on surface protein expression, and understand mechanisms of resistance that are invisible in traditional proteomic datasets. Investors and innovation arms rely on it to evaluate the translational relevance of pipeline targets, while AI companies integrate the data to train predictive models with richer, clinically grounded features.

How does your data help reduce clinical trial risk?

By providing clinically validated expression data from real tumors, our dataset helps teams validate mechanisms of action, predict off-target effects, and select patients more precisely. This translates to better trial design, lower risk of failure, and more efficient resource allocation.

Can Champions support custom studies using this platform?

Yes. In addition to our existing dataset, Champions offers bespoke surface proteomics studies using client-specified models or indications. We can generate custom profiles, validate specific targets, and integrate findings with pharmacological studies or PDX models.

How can I get started or speak with a data expert?

You can request access to the Data Room or schedule a consultation with our data science and translational oncology team by completing the contact form on this page or emailing data@championsoncology.com. We’ll guide you through the dataset, potential applications, and partnership options.